Partnering in Technologies

Our experience

Scientists at our major research sites, together with our academic and industry partners, are pursuing novel technologies to support therapeutic advances in areas of key unmet medical need. We have the ambition to identify and translate the most promising technology innovations into impactful applications across a broad range of research fields.

Our Technology Partnering Interests

Our partnering interests offer various opportunities for collaboration:

• Hit/Tool/Lead generation technologies: Rapid generation of compounds for the validation and progression of new therapeutic concepts (NTCs)

• Technologies which help to accelerate drug discovery and drug development

• Applications of artificial intelligence and machine/deep learning in drug discovery and translational sciences

• Advanced computational biology methods and analytics to identify and evaluate NTCs

• New approaches to access hard-to-drug targets

• Target engagement, target ID and target deconvolution

• (Targeted) Intracellular delivery technologies

• Long-acting injectables and depot technologies for sustained drug release

• New modalities beyond small molecules to address difficult targets and expand our NCE target space

Our Biotherapeutic Technology Partnering Interests

Our partnering interests offer various opportunities for collaboration:

• In-silico and AI discovery and optimization platforms for biotherapeutics

• Biologic enabling technologies and formats supporting therapeutic areas (Oncology, CardioMetabolic diseases, Immunology and Inflammation, Respiratory diseases, Retinal Health, and Central Nervous System diseases)

• Technologies to enable function-driven first-in-class antibody identification

• New technologies for half-life extension systemically and in the eye

• Accelerating timelines from tool to lead, lead to drug, as well, as in drug development.